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Abstract
Introduction: Candida prophylaxis in ICU is still a matter of debate. Oral chemoprophylaxis has been advocated to
reduce the incidence of Candida colonisation and infection.
Methods: We performed a randomised trial studying a single drug (nystatin) versus control in surgical/trauma ICU
patients. Multiple-site testing for fungi was performed in each patient on ICU admission (T0) and subsequently
every 3 days (T3, T6, T9, and so forth). The primary evaluation criterion was the time course of the corrected
colonisation index.
Results: Ninety-nine patients were enrolled. At admission, 69 patients exhibited Candida colonisation: the most
frequently colonised body sites were the stomach and the pharynx. The most frequent isolated species was
Candida albicans. The corrected colonisation index was similar in the two groups at T0 (P = 0.36), while a
significant statistical difference was observed between the treatment and control groups at T6 (median 0.14 and
0.33, respectively; P = 0.0016), at T9 (median 0.00 and 0.28, respectively; P = 0.0001), at T12 (median 0.00 and 0.41,
respectively; P = 0.0008), and at T15 (median 0.00 and 0.42, respectively; P <0.0003). The same results were
obtained in the subgroup of patients already colonised at ICU admission.
Conclusion: This trial shows that nystatin prophylaxis significantly reduces fungal colonisation in surgical/trauma
ICU patients, even if already colonised.
Trial registration: ClinicalTrials.gov: NCT01495039
Introduction
The challenge posed by nosocomial fungal infections in
critically ill patients has become increasingly apparent
over the past 20 years. Candida species are now among
the leading pathogens in ICUs in both Europe and the
United States [1-6]. The incidence of nosocomial candi-
daemia has dramatically increased and has been associated
with high overall (35 to 80%) and attributable (30 to 40%)
mortality [3]. Moreover, it has been reported that the
length of stay of critically ill patients who survived candi-
daemia was prolonged from 8 to 30 days with a significant
increase of nursing workload [7]. Candidaemic patients
needed a prolongation of mechanical ventilatory support
of 10 days [8]. Candidaemia is associated with high
morbidity, high mortality, and the significant use of addi-
tional resources.
Colonisation by Candida species is the leading risk
factor for infection, and several elements support the
assumption that multiple- site colonisation is a prerequi-
site for subsequent infection [9-12]. Several risk factors
can promote further invasion with possible secondary
haematogenous dissemination; among these risk factors,
surgical procedures seem to play a key role [13].
Assuming the risk of death is similar in multiple-site
colonised surgical patients and in those with proven candi-
diasis [14], several studies have focused on the degree of
colonisation and screening. Pittet and colleagues estab-
lished the degree of colonisation with the Candida coloni-
sation index (CI) and found a strong correlation between
colonisation intensity (that is, CI > 0.5) and invasive infec-
tions [9]. The same authors showed that considering
heavy colonised body sites with the corrected colonisation
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index (CCI) enhances the discriminatory power of the CI,
with higher (100%) sensitivity, specificity, positive predic-
tive, and negative predictive values than the CI [9].
For these reasons, oral chemoprophylaxis has been
advocated for ICU patients, and in particular for surgical
ICU patients, with the aim to reduce the incidence of
heavy colonisation and infection [15], although whether
this approach should be implemented remains controver-
sial. Oral nystatin prophylaxis efficiently prevented
Candida species colonisation both in medical and surgi-
cal patients that were not colonised at admission to the
ICU [16]. Since colonisation can be observed on admis-
sion in up to 50% of ICU patients [17,18] a considerable
cohort was excluded, making these positive results not
applicable to all ICU populations.
We therefore decided to perform a randomised con-
trolled trial to evaluate the time course of CCI in a sur-
gical/trauma ICU population, including those colonised
at admission, undergoing nystatin prophylaxis.
Materials and methods
We performed a randomised, open-label, single-centre
study with blinded assessment of the objective primary
evaluation criterion. We studied a single drug (nystatin)
versus control. The study was approved by the Ethics
Committee of the Policlinico Hospital, Bari, Italy and was
conducted in accordance with the Helsinki Declaration
(ClinicalTrials.gov: NCT01495039).
The study was performed from November 2008 to
August 2009 (date of final data collection for the primary
outcome measure). The primary evaluation criterion was
the time course of the CCI; the secondary evaluation cri-
terion was occurrence of a fungal infection.
Study population
The patients or their next of kin provided informed con-
sent for participation in the study. The inclusion criteria
were: surgical patients admitted to our ICU > 18 years of
age and expected to require invasive mechanical ventila-
tion for more than 48 hours. The exclusion criteria were:
pregnancy, proven Candida infection, prophylactic or
curative antifungal treatment within the last 2 months,
contraindication to oral drug administration, known
allergy to nystatin or its derivatives, and prior inclusion in
the study.
Reasons for admission, demographic characteristics,
immune status, and the Sequential Organ Failure Assess-
ment score were recorded on admission. The duration of
mechanical ventilation, the duration of antibiotic and
corticosteroid therapy, the length of stay in the ICU, the
route of nutrition (that is, enteral vs. parenteral), and
mortality were also recorded. In cases of residual gastric
volume > 500 ml/24 hours or vomiting, the patient was
excluded from the analysis. Risk factors for Candida
infection were identified and recorded as previously sug-
gested (that is, diabetes, previous antibiotic and corticos-
teroid therapy or dialysis, central venous catheter,
parenteral nutrition, multiple transfusions, pancreatitis,
chronic renal failure, immunosuppressive therapy other
than steroids, leucopenia (white blood cells < 4,000/mm))
[19]. Patients were randomised to one of the two study
groups, according to a randomisation sealed envelope
opened on admission to the ICU, to receive either sys-
tematic nystatin prophylaxis (2 × 106 U/day administered
three times daily via the nasogastric tube; group N) or no
nystatin prophylaxis as control (group C).
Definitions and mycological assessment
Multiple-site testing for fungi included tracheal secretions,
swab, stomach contents, pharyngeal, rectal and groin skin-
fold swabs, urine, and blood. These tests were performed
in each patient at ICU admission (T0) and subsequently
every 3 days throughout the ICU stay (T3, T6, T9, and so
forth). The specimens were placed in a dry medium and
taken to the Mycology Laboratory. Group assignment was
not indicated on the specimens, so the mycologists were
therefore blinded to treatment allocation. Each specimen
was directly microscopically examined and cultured on
Sabouraud media. The attending physicians were not
aware of the results of the colonisation samples, and there-
fore no empirical or pre-emptive antifungal therapy was in
place in enrolled patients.
Colonisation was assessed for each body site specimen,
and yeasts were identified. Fungal colonisation was defined
as the presence of the same yeast on one or more of the
six distinct body sites tested (blood sample excepted). The
CI was calculated for each multiple-site testing as the ratio
between the number of distinct body sites colonised by
Candida species (except blood) and the total number of
sites tested. The CCI was calculated for each time point as
the product of the CI multiplied by the ratio of the num-
ber of distinct nonblood body sites showing heavy growth
to the total of body sites growing Candida species. Fungal
infection was defined as either the presence of candidae-
mia or the identification of Candida species in a normally
sterile body site, associated with severe sepsis and negative
tests for bacteria. During the study period, adverse events
related to the study drug were monitored (that is, diar-
rhoea, nausea, vomiting, intestinal pain, urticarial skin
reactions).
Outcome measures and statistical analysis
Continuous variables are expressed as the mean ± standard
deviation or median (interquartile range). Categorical vari-
ables were compared by chi-square test or Fisher’s exact
test. Student’s t test was used to compare normally distrib-
uted continuous variables, and the Mann-Whitney U test
was used to analyse variables not normally distributed.
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All P values were two-tailed. Statistical significance was set
at P ≤ 0.05. For an estimated rate of fungal colonisation
reaching approximately 60% in ICU patients, 49 patients
per group had to be enrolled in the study to show a 50%
reduction in fungal colonisation, with an a error of 5% and
a b error of 20%.
Results
Of 260 patients assessed for eligibility, 128 were rando-
mised to the two study groups. Of these randomised
patients, 99 completed the study (61 men, 38 women):
49 patients were randomised to group N and 50 patients
to group C (see Figure 1 for trial flow).
The two groups were well matched in terms of age,
sex, baseline morbidity, risk factors for Candida infec-
tion, and reason for admission to the ICU. The mean
age was 56 ± 20 years and the mean Sequential Organ
Failure Assessment score was 7 ± 2. The reason for ICU
admission was abdominal surgery in 15 patients, neuro-
surgery in 45 patients, and trauma in 39 patients. The
most frequent risk factors for Candida infection were
central venous catheters (n = 99), followed by antibiotic
therapy (n = 82) and parenteral nutrition (n = 56). The
duration of mechanical ventilation as well as the ICU
stay were similar between the two groups (Table 1).
At admission, 69 patients exhibited Candida colonisa-
tion (34 in group N and 35 in group C) while 30 patients
were not colonised (15 patients in both groups). The
most frequently colonised body sites were the stomach
and the pharynx (58% and 47% of the total sample
obtained, respectively), followed by the trachea (27%) and
the rectum (20%). There were no differences between the
Assessed for eligibility (n=260) 
Excluded  (n= 132) 
Not meeting inclusion criteria (n=120) 
Declined to participate (n=8) 
Other reasons (n=4) 
 
Analysed  (n=49) 
 Excluded from analysis (n=0) 
Lost to follow-up (ICU stay < 48 hours) (n=5) 
Discontinued intervention (n=0) 
 
Allocated to intervention (n=75) 
Did not received allocated intervention  
(residual gastric volume greater than 500 ml/24 h) (n=21: 
abdominal surgery =11, neurosurgery =2, trauma =8) 
) 
Lost to follow-up (ICU stay < 48 hours ) (n=3) 
Discontinued intervention (n=0) 
 
Analysed  (n=50) 











Allocated to control group (n=53) 
 
Received allocated intervention (n=53) 
Figure 1 Flow diagram of progress through the phases of this randomised trial for the two groups.
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two groups at this time. The most frequent isolated Can-
dida species at T0 was Candida albicans (71%), followed
by Candida glabrata (14%) and Candida krusei (1%). Fig-
ure 2 depicts the CCI for the two groups over time. The
CCI was comparable in the two groups at T0 (P = 0.36),
while a significant statistical difference was observed
between group N and group C at T6 (median 0.14 and
0.33, respectively; P = 0.0016), at T9 (median 0.00 and
0.28, respectively; P = 0.0001), at T12 (median 0.00 and
0.41, respectively; P = 0.0008), and at T15 (median 0.00
and 0.42, respectively; P <0.0003).
During hospitalisation in the ICU the proportion of
positive stomach samples significantly decreased in the
treatment group (from 59 to 49%) as opposed to the
control group (from 58 to 74%; P <0.00009) at T6, and
this difference persisted over time. At the end of the
study period, the percentage of positive rectum samples
significantly decreased in group N (from 12 to 8%)
while it increased from 28 to 55% in group C (P
<0.0001). A significant reduction of positive urinary
samples was also noticed in group N (from 10 to 0%)
compared with group C (from 6 to 25%; P <0.016), No
difference was detected in pharyngeal samples (Table 2
and Figure 3).
Among patients colonised at admission, no statistical
difference in CCI was found between the two groups at
T0 and T3 (P = 0.26 and P = 0.18, respectively). At T6,
however, group N showed a statistical significant
reduction of CCI (median 0.14 in group N vs. 0.42 in
group C, P = 0.0007), and this difference persisted at
T9 (median 0.14 vs. 0.33, respectively; P = 0.0004), at
T12 (median 0.00 vs. 0.42, respectively; P = 0.0005),
and at T15 (median 0.00 vs. 0.42, respectively; P =
0.0005) (Figure 4). In the subgroup of patients not
colonised at admission, a statistically significant
increase in the CCI was also observed in group C as
compared with group N at T9 (median 0.14 vs. 0.00,
respectively; P = 0.04), but this significance did not
persist over time and the very low number of the
patients did not allow any analysis.
No fungal infection was recorded, even in heavily
colonised patients. No clinically adverse effect related to
nystatin therapy was recorded.
Discussion
The main finding of the present study is that systematic
nystatin prophylaxis significantly reduces the develop-
ment of Candida species colonisation and that it
Table 1 Demographic characteristics of patients included in the two study groups
Nystatin group (n = 49) Control group (n = 50) P value
Age (years) 54 ± 22 58 ± 19 0.27
Female/male 18/31 20/30 0.80
Sequential Organ Failure Assessment score 7 ± 2 7 ± 2 0.69
APACHE II score 19.5 ± 7 19.3 ± 8 0.89
Type of admission
Abdominal surgery 6 (12%) 9 (18%) 0.42
Neurosurgery 19 (39%) 26 (52%) 0.19
Trauma 24 (49%) 15 (30%) 0.05
Duration of hospital stay before ICU admission (days) 2 ± 4 2 ± 4 0.6
Duration of mechanical ventilation (days) 13 ± 11 13 ± 12 0.93
Duration of ICU stay (days) 15 ± 14 15 ± 14 0.86
Risk factors
Diabetes mellitus 13 (26%) 9 (18%) 0.3
Neutropenia (WBC < 4,000/mm3) 0 0
Steroids (days -7 to 3) 11 (22%) 7 (14%) 0.96
Multiple transfusions 12 (24%) 13 (26%) 0.86
Pancreatitis (days -7 to 0) 0 2 (4%) 0.55
Chronic renal failure 0 1 (2%) 0.31
Immunosuppressive agents other than steroids (days -7 to 0) 0 0
Dialysis (days 1 to 3) 0 1 (2%) 0.31
Total parenteral nutrition (days 1 to 3) 29 (59%) 27 (54%) 0.36
Central venous catheter (days 1 to 3) 49 (100%) 50 (100%)
Antibiotic therapy (days 1 to 3) 40 (81%) 42 (84%) 0.63
Acute renal failure 0 0
Mortality 11 (22%) 13 (26%) 0.68
Data presented as mean ± standard deviation or n (%). Risk factors are recorded as suggested by Ostrosky-Zeichner and colleagues [19]. APACHE, Acute
Physiology and Chronic Health Evaluation; WBC, white blood cells.
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significantly reduces the CCI after 6 days of treatment in
patients already colonised at ICU admission.
Invasive candidiasis infections are associated with an
increased morbidity and mortality in ICU patients (30 to
40%), depending on the severity of underlying disease, the
Candida species involved, and the timing and choice of
antifungal treatment [1]. Early and adequate antifungal
treatment is well known to be independently associated
with a reduction of hospital mortality [20]. This is the rea-
son why early antifungal treatments, such as prophylaxis,
pre-emptive, or empiric therapies, have progressively
emerged; however, most of these strategies lack an evi-
dence base that would establish them as the standard of
care. Several studies evaluated the effects of prophylaxis or
pre-emptive therapy on fungal infection and mortality,
and most of them compared fluconazole with placebo
[21,22]. Some concerns remain about the use of azoles for
prophylaxis, including the emergence of resistance among
previously susceptible strains (C. albicans) or a shift to less
susceptible or resistant non-albicans species (C. glabrata
or C. krusei), increased costs, and adverse events [23,24].
Moreover, because patient populations, dosing regimens,
severity of illness, and definitions of infection and other
outcome measures varied between trials, conclusions are
difficult to extrapolate. Current recommendations limit
the use of antifungal prophylaxis to high-risk adult
patients admitted to those ICUs that have very high rates
of invasive candidiasis, and advocate against the wide-
spread use of an antifungal in all ICU patients [25,26].
In this context, the use of nystatin may present a ratio-
nale alternative [27]. Nystatin, like amphotericin B, is a
nonabsorbable polyene with a wide antifungal activity,
especially against Candida species, including C. glabrata
and C. krusei. Although most species of Candida isolated
in ICU patients remain susceptible to azoles, indiscrimi-
nate use of such drugs may lead to the spread of C. krusei
and C. glabrata, intrinsically resistant to and dose-depen-
dently sensitive to azoles, respectively [28]. In contrast,
primary resistance to polyenes among Candida species is
limited to Candida lusitaniae and to some strains of
Control group 
Nistatin group 








Time course of  Corrected Colonization Index 
Figure 2 Course of the corrected colonisation index over time. Course of the corrected colonisation index (CCI) over time in the treatment
group (white bars) and the control group (black bars). Illustrated are the daily median values (filled circles), and the 25th and 75th percentiles -
that is, the interquartile range (borders of the box). Data in parentheses are the number of patients in each of the two study groups over time.
*P <0.05.
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Candida guillermondii, and resistance seldom develops
during treatment [29]. Moreover, no adverse effects of
nystatin are reported. Azoles are generally well tolerated,
but side effects such as hepatic dysfunction are possible.
These risks, even if low, could be more difficult to accept
in the setting of prophylaxis in critically ill patients. The
third advantage of oral nystatin is its low cost, making
this strategy potentially highly cost-effective.
Nonabsorbable polyenes are integrated in most selec-
tive decontamination of the digestive tract regimens,
and a recent meta-analysis showed that they significantly
reduce fungal carriage and overall fungal infections, but
without impact on fungemia [30]. This meta-analysis,
however, included only two trials testing nystatin pro-
phylaxis. Moreover, the majority of selective decontami-
nation of the digestive tract regimens included either
concurrent systemic or topical antibacterial antibiotic
prophylaxis in the treatment group, which might
increase the risk of fungal infection in that group rela-
tive to the placebo group. A recent study investigated
the effect of oral nystatin prophylaxis to prevent Can-
dida species colonisation [16]. This trial, however,
included both medical and surgical patients and
excluded those patients who exhibited baseline Candida
species colonisation. Since colonisation can be observed
Table 2 Total and positive samples obtained in the two
groups at each time-point for every site
Sample T0 T3 T6 T9 T12 T15
Trachea Positive samples in group C 16 18 15 16 11 6
Positive samples in group N 11 16 12 11 5 1
Total samples obtained 99 81 72 53 33 22
Stomach Positive samples in group C 29 27 26 16 15 7
Positive samples in group N 29 21 19 13 9 1
Total samples obtained 99 86 72 57 37 24
Pharynx Positive samples in group C 23 23 20 18 13 7
Positive samples in group N 24 22 15 18 11 8
Total samples obtained 95 73 65 53 33 23
Skin Positive samples in group C 2 3 8 6 6 4
Positive samples in group N 0 1 4 0 2 2
Total samples obtained 100 86 72 58 37 28
Rectum Positive samples in group C 13 8 15 13 12 6
Positive samples in group N 6 7 12 8 1 1
Total samples obtained 95 79 72 57 33 24
Urine Positive samples in group C 3 6 8 7 7 3
Positive samples in group N 5 5 5 4 1 0
Total samples obtained 99 86 72 59 36 28
Blood Positive samples in group C 0 0 0 0 0 0
Positive samples in group N 0 0 0 0 0 0
Total samples obtained 99 86 72 59 37 28
Group N, nystatin group; group C, control group.
Figure 3 Colonisation of different body sites. Percentage of patients colonised during the study period in four different body sites: stomach,
rectum, trachea, and urine. Black bars, control group; white bars, nystatin group. *P <0.05 between groups at every time (T0, T3, and so forth).
Pts, patients.
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on admission to the ICU in almost 50% of patients
[17,18], a considerable cohort of ICU population was
excluded in this latter study, making these positive
results not applicable to all ICU patients.
The present trial showed that oral nystatin prophylaxis
started on the day of admission is significantly effective
in reducing heavy fungal colonisation, even in baseline
colonised patients. This finding was presumably related
to the efficacy of oral nystatin to significantly reduce the
proportion of positive gastrointestinal sites (for example,
stomach and rectum), as shown in the treatment group.
Accordingly, the CCI regularly decreased over time in
patients receiving nystatin, whereas it tended to increase
in controls. No adverse events developed during the
study period, confirming that this polyene is a safe choice
in the surgical ICU population. Interestingly, nystatin
prophylaxis also reduces colonisation in the urinary tract,
which is now advocated as the easier and simpler marker
for heavily colonised patients [31]. A possible explanation
could be that oral nystatin, by reducing gastrointestinal
fungal carriage, can also help to control genital and peri-
neal fungal colonisation, thus lowering the risk of retro-
grade access to the urinary tract, especially in the
presence of indwelling bladder catheters. Moreover, oral
nystatin increases costs only by €1.1/patient/day of treat-
ment (data not shown).
In the present study, almost 70% of included patients
were colonised at admission. This was a surprising finding.
While neurosurgical and abdominal surgery patients have
several comorbidities and risk factors (that is, long hospital
stay, central venous catheter, parenteral nutrition, antibio-
tic therapy) that may predispose to subsequent Candida
colonisation, this is usually not true for trauma patients.
When we analysed the subgroup of trauma patients, how-
ever, we noted that almost 50% of them were colonised at
admission to the ICU - suggesting that, in many cases,
Control group 
Nistatin group 









Time course of  Corrected Colonization Index 
in patients already colonized at ICU admission 
Figure 4 Corrected colonisation index over time in patients already colonised at admission to the ICU. Course of the corrected
colonisation index (CCI) over time in the treatment group (white bars) and the control group (black bars), considering only patients who were
already colonised at admission to the ICU. Illustrated are the daily median values (filled circles), and the 25th and 75th percentiles - that is, the
interquartile range (borders of the box). Data in parentheses are the number of patients in each of the two study groups over time. *P <0.05.
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fungal colonisation can be community acquired and not
only hospital related. Further trials are needed, in our opi-
nion, to investigate this hypothesis.
Candida colonisation is very common among ICU
patients, reaching 60% in non-neutropenic critically ill
patients [32], and is a well-known risk factor for invasive
candidiasis [9,13] since changes in the ecology of the
endogenous flora may promote Candida species over-
growth on mucosal and skin surfaces [11] and transloca-
tion across the gut barrier, mostly when its integrity is
lost [12,33]. Candida colonisation can be statistically
associated with a higher frequency of clinical manifesta-
tion or even higher mortality [14]. Based on the previous
consideration, we suggest the use of nystatin for fungal
pre-emptive therapy in high-risk colonised patients on
admission to the ICU as a rationale choice, since it could
be effectively used in almost all ICU patients with CCI >
0.4 without increased risk of adverse events. Calculating
the CCI, however, is time consuming and resource con-
suming and is not always feasible. When the CCI is not
known we favour nystatin use in those patients expected
to require a long ICU stay. Only under these conditions
will the risk-benefit and cost-benefit ratios for prophy-
laxis reflect an advantage for the patient [34].
Unfortunately, no definitive conclusion regarding the
effect of nystatin prophylaxis on Candida infection can be
drawn from our study because none of the included
patients, even if heavily colonised, developed the infection.
A probable hypothesis to explain this unexpected result is
that, in our ICU, a rigid surveillance policy of central
venous catheters was undertaken, including strict asepsis
during insertion, careful medication, and early removal as
soon as possible (median 3 days). This approach, together
with a rapid interruption of parenteral nutrition in favour
of the enteral route, could justify why no episode of Can-
dida infection was documented during the study period.
Moreover, the number of patients with abdominal surgery
is low, especially in comparison with neurosurgical
patients. This factor could be important because abdom-
inal surgery is a risk factor for invasive candidiasis more
than other types of surgery. This trial, finally, was designed
to investigate the effect of nystatin prophylaxis on fungal
colonisation during the ICU stay and not to detect any
reduction in fungal infection, which would have required a
larger number of patients.
Other limitations of the present study included the sin-
gle-centre, open-label design and the small sample size.
The inclusion criteria adopted (surgical patients expected
to require invasive mechanical ventilation for more than
48 hours), however, selected a homogeneous population of
ICU patients, treated by the same staff adopting the same
protocols to prevent infection - assuring, in our opinion,
consistent and reliable results. Larger trials are warranted
to elucidate the impact of nystatin prophylaxis on the
infection rate and mortality in critically ill patients.
Conclusion
The present trial shows that nystatin pre-emptive ther-
apy in surgical/trauma ICU patients significantly reduces
fungal colonisation, even in those colonised at admis-
sion. Moreover, when CCI is not calculated, we suggest
nystatin use in those patients expected to require a long
intensive care stay. This approach could contain antifun-
gal therapy costs. Further clinical data are needed, how-
ever, to better identify patients who might warrant
antifungal prophylaxis using drugs with low risk of resis-
tant stain emergence, in order to drastically reduce fun-
gal-related morbidity and mortality.
Key messages
• The incidence of nosocomial candidemia has dra-
matically increased and has been associated with
high overall (35 to 80%) and attributable (30 to 40%)
mortality.
• An early and adequate antifungal treatment is
independently associated with a reduction of hospital
mortality.
• Oral nystatin prophylaxis started at the day of
admission is significantly effective in reducing fungal
colonisation, even in baseline colonised ICU patients.
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